SNDX
Price:
$19.1
Market Cap:
$1.63B
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with Nation...[Read more]
Industry
Biotechnology
IPO Date
2016-03-02
Stock Exchange
NASDAQ
Ticker
SNDX
According to Syndax Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.52B. This represents a change of 4.19% compared to the average of 1.46B of the last 4 quarters.
The mean historical Enterprise Value of Syndax Pharmaceuticals, Inc. over the last ten years is 532.00M. The current 1.52B Enterprise Value has changed 28.49% with respect to the historical average. Over the past ten years (40 quarters), SNDX's Enterprise Value was at its highest in in the March 2024 quarter at 1.91B. The Enterprise Value was at its lowest in in the June 2015 quarter at 0.
Average
532.00M
Median
214.65M
Minimum
79.13M
Maximum
1.47B
Discovering the peaks and valleys of Syndax Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 237.70%
Maximum Annual Enterprise Value = 1.47B
Minimum Annual Increase = -56.30%
Minimum Annual Enterprise Value = 79.13M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.23B | -16.71% |
2022 | 1.47B | 56.94% |
2021 | 938.70M | 13.92% |
2020 | 823.99M | 237.70% |
2019 | 244.00M | 208.33% |
2018 | 79.13M | -46.81% |
2017 | 148.77M | 83.71% |
2016 | 80.98M | -56.30% |
2015 | 185.29M | 55.65% |
2014 | 119.05M | 38.45% |
The current Enterprise Value of Syndax Pharmaceuticals, Inc. (SNDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.21B
5-year avg
941.36M
10-year avg
532.00M
Syndax Pharmaceuticals, Inc.’s Enterprise Value is greater than Cogent Biosciences, Inc. (1.08B), greater than Cullinan Oncology, Inc. (930.13M), greater than KalVista Pharmaceuticals, Inc. (506.03M), greater than Mersana Therapeutics, Inc. (138.92M), greater than Pliant Therapeutics, Inc. (762.35M), less than Revolution Medicines, Inc. (6.80B), greater than Viridian Therapeutics, Inc. (813.50M), greater than Inozyme Pharma, Inc. (343.89M), greater than Aerovate Therapeutics, Inc. (24.46M), less than Keros Therapeutics, Inc. (1.58B), greater than Mineralys Therapeutics, Inc. (490.57M), greater than Replimune Group, Inc. (632.78M), less than Vaxcyte, Inc. (11.96B), greater than Larimar Therapeutics, Inc. (486.93M), less than Merus N.V. (2.79B), greater than Sutro Biopharma, Inc. (437.33M), less than Cytokinetics, Incorporated (6.96B), less than DICE Therapeutics, Inc. (2.21B), less than Edgewise Therapeutics, Inc. (1.60B), less than Karuna Therapeutics, Inc. (12.43B), less than Dyne Therapeutics, Inc. (2.73B),
Company | Enterprise Value | Market cap |
---|---|---|
1.08B | $1.15B | |
930.13M | $1.04B | |
506.03M | $531.63M | |
138.92M | $165.61M | |
762.35M | $782.51M | |
6.80B | $6.99B | |
813.50M | $900.21M | |
343.89M | $312.42M | |
24.46M | $54.85M | |
1.58B | $1.97B | |
490.57M | $558.43M | |
632.78M | $708.49M | |
11.96B | $12.45B | |
486.93M | $513.64M | |
2.79B | $3.41B | |
437.33M | $337.69M | |
6.96B | $6.36B | |
2.21B | $2.27B | |
1.60B | $1.64B | |
12.43B | $12.60B | |
2.73B | $3.32B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Syndax Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Syndax Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Syndax Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Syndax Pharmaceuticals, Inc. (SNDX)?
What is the 3-year average Enterprise Value for Syndax Pharmaceuticals, Inc. (SNDX)?
What is the 5-year average Enterprise Value for Syndax Pharmaceuticals, Inc. (SNDX)?
How does the current Enterprise Value for Syndax Pharmaceuticals, Inc. (SNDX) compare to its historical average?